Much remains to be learned regarding anti-HLA antibodies in transplantation. A few of the examples where additional knowledge is needed include: 1) Factors that influence the marked variations in clinical phenotypes exhibited by antibody-mediated processes, 2) Processes that determine whether cellular or humoral mechanisms (or both) predominate in the alloresponse to human allografts, 3) Factors that influence antibody production, and responses to antihumoral therapies, 4) the extent to which antibody elimination is needed to achieve optimal results with antihumoral therapies.
What You'll Take Away from His Talk:
Accumulation of knowledge regarding anti HLA alloantibodies in transplantation is proceeding at a fast pace.
Requisite basic science in mice and humans is substantial but a broader and deeper understanding is needed.